Research programme: asthma/allergy therapy - Johnson & Johnson Pharmaceutical Research and Development, LLC/Boehringer Ingelheim

Drug Profile

Research programme: asthma/allergy therapy - Johnson & Johnson Pharmaceutical Research and Development, LLC/Boehringer Ingelheim

Alternative Names: Asthma/allergy therapy research programme - 3-Dimensional Pharmaceuticals/Boehringer Ingelheim

Latest Information Update: 03 Mar 2008

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Johnson & Johnson Pharmaceutical Research & Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
  • 15 May 2001 Preclinical development for Asthma in USA (Unknown route)
  • 15 May 2001 Preclinical development for Allergy in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top